Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.2400+0.0700 (+2.21%)
At close: 01:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.1700
Open3.1500
BidN/A x N/A
AskN/A x N/A
Day's range3.1500 - 3.2400
52-week range2.9341 - 6.7764
Volume31,545
Avg. volume2,382
Market cap115.416M
Beta (5Y monthly)1.40
PE ratio (TTM)N/A
EPS (TTM)-1.1300
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million

    NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed its previously announced overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”). Pursuant to the Offering, Eupraxia issued 8,260,435 Shares at a price of C$4.10 per Sha

  • GlobeNewswire

    Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million

    NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has priced its previously announced overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”). Pursuant to the Offering, Eupraxia will issue 7,317,000 Shares at a price of C$4.10 per

  • GlobeNewswire

    Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million

    NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for total gross proceeds of approximately $30 million. The Offering will be priced in the context of the market, wi